Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy

JACC: Cardiovascular Interventions

Volumn 8, Issue 3, 2015, Pages 404-410

  Cutlip, Donald E ^a,b   Kereiakes, Dean J ^c   Mauri, Laura ^b,d   Stoler, Robert ^e   Dauerman, Harold L ^f  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

antiplatelet therapy; stent; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; WARFARIN; ZOTAROLIMUS; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; RAPAMYCIN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; DRUG ELUTING CORONARY STENT; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; STENT THROMBOSIS; TREATMENT REFUSAL; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; CORONARY THROMBOSIS; DEVICES; DRUG COMBINATION; DRUG ELUTING STENT; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; PROSTHESIS; REGISTER; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGED; ASPIRIN; CARDIOVASCULAR AGENTS; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK FACTORS; SIROLIMUS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926407776     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.10.017     Document Type: Article

References (26)

1. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
2. I. Iakovou, T. Schmidt, and E. Bonizzoni Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
3. A. Farb, and A.B. Boam Stent thrombosis redux - the FDA perspective New Engl J Med 356 2007 984 987
4. C.L. Grines, R.O. Bonow, and D.E. Casey Jr. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians Catheter Cardiovasc Interv 69 2007 334 340
5. S.J. Park, D.W. Park, and Y.H. Kim Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382
6. M. Valgimigli, G. Campo, and M. Monti Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
7. C.W. Lee, J.M. Ahn, and D.W. Park Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial Circulation 129 2014 304 312
8. L. Mauri, D.J. Kereiakes, and S.L. Normand Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions Am Heart J 160 2010 1035 1041
9. H.C. Gwon, J.Y. Hahn, and K.W. Park Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 505 513
10. B.K. Kim, M.K. Hong, D.H. Shin for the RESET Investigators A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 2012 1340 1348
11. F. Feres, R.A. Costa, and A. Abizaid Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
12. T. Kimura, T. Morimoto, Y. Nakagawa for the j-Cypher Registry Investigators Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation Circulation 119 2009 987 995
13. S.S. Naidu, M.W. Krucoff, and D.R. Rutledge Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study J Am Coll Cardiol Intv 5 2012 626 635
14. R. Mehran, U. Baber, and P.G. Steg Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study Lancet 382 2013 1714 1722
15. S. Silber, A.J. Kirtane, and J.A. Belardi Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following Resolute zotarolimus-eluting stent implantation Eur Heart J 35 2014 1949 1956
16. D.E. Cutlip, S. Windecker, R. Mehran for the Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
17. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction New Engl J Med 329 1993 673 682
18. A. Jeremias, B. Sylvia, and J. Bridges Stent thrombosis after successful sirolimus-eluting stent implantation Circulation 109 2004 1930 1932
19. J.W. van Werkum, A.A. Heestermans, and A.C. Zomer Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry J Am Coll Cardiol 53 2009 1399 1409
20. I. Ferreira-Gonzalez, J.R. Marsal, and A. Ribera Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year J Am Coll Cardiol 60 2012 1333 1339
21. M. Joner, A.V. Finn, and A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
22. M. Joner, G. Nakazawa, and A.V. Finn Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 2008 333 342
23. A.V. Finn, G. Nakazawa, and M. Joner Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510
24. H.H. Choi, J.S. Kim, and D.H. Yoon Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography Int J Cardiovasc Imaging 28 2012 491 497
25. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol 62 2013 1915 1921
26. D.E. Kandzari, M.B. Leon, I. Meredith, J. Fajadet, W. Wijns, and L. Mauri Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents J Am Coll Cardiol Intv 6 2013 504 512